Delving into the Latest Updates on Furazolidone with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

3-(5'-Nitrofurfuralamino)-2-oxazolidone, 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone, 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone

+ [10]

Target

DNA

Mechanism

DNA inhibitors(DNA inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System DisordersOther Diseases

Active Indication

CholeraDysenteryEnteritis+ [3]

Inactive Indication-

Originator Organization

Shire Development LLC

Active Organization

Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd.

Inactive Organization

Shire Development LLC

Drug Highest PhaseApproved

First Approval Date

US (20 Jan 1958),

Enteritis

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC8H7N3O5

InChIKeyPLHJDBGFXBMTGZ-UHFFFAOYSA-N

CAS Registry67-45-8

The purpose of this study was to compare the efficacy of 14-day eradication of Helicobacter pylori with different doses of Keverprazan combined with Amoxicillin dual therapy and Keverprazan-based bismuth quadruple therapy and compare the adverse reactions, compliance, and factors affecting the efficacy of eradication schemes among different groups.

Start Date01 Mar 2025

Sponsor / Collaborator

Jiangsu Provincial People's Hospital

ChiCTR2400093569

/ SuspendedNot Applicable

Efficacy and safety of anelazole diphtherapy and furazolidone-based bismuth quadruphtherapy for eradication of Helicobacter pylori: a prospective, multicentre, open-label, randomised controlled clinical study

Start Date15 Dec 2024

Sponsor / Collaborator-

IRCT20230827059273N1

/ SuspendedPhase 3IIT

Evaluation of success rate of two treatment clarithromycin baced and furazolidone baced with and without pyloshot in patients with refractory Helicobacter pylori infection

Start Date20 Mar 2024

Sponsor / Collaborator

Ardabil University of Medical Sciences

100 Clinical Results associated with Furazolidone

Login to view more data

100 Translational Medicine associated with Furazolidone

Login to view more data

100 Patents (Medical) associated with Furazolidone

Login to view more data

1,717

Literatures (Medical) associated with Furazolidone

02 Jan 2025·Journal of Environmental Science and Health, Part B

Fmoc-Pro-Phe-OMe dipeptide carbon sensor for simultaneous detection of chloramphenicol (CP) and furazolidone (FZ) toxic residues in food samples

Article

Author: K.N, Harish ; R B, Raghavendra ; Reddy, Sathish ; G, Nagendra ; E, Nirajan ; K J, Abhishek ; Kumari, Dalli ; K J, Gururaj

In this work, we fabricated the Fmoc-Pro-Phe-OMe modified carbon paste electrode (FPPO/MCPE) and used it for electrochemical detection of CP and FZ in a 0.1 M phosphate buffer solution (pH = 7). We characterized the Fmoc-Pro-Phe-OMe and applied it for the electrochemical detection of CP and FZ. The Mass spectroscopy, ¹HNMR, and FTIR measurements confirm the Fmoc-Pro-Phe-OMe chemical structure. Studying electrochemical sensor characteristics, variation of scan rate parameters, and electrode surface area is crucial for understanding and optimizing the performance of modified and unmodified carbon paste electrodes. The FPPO/MCPE-modified carbon paste electrode has better sensing capabilities than the unmodified bare carbon paste electrode (BCPE). The FPPO/MCPE sensor has two linear ranges: 50-450 μM (CP) with a detection limit of 0.014 μM and 50-450 μM (FZ) with a detection limit of 0.015 μM. The FPPO/MCPE sensor is highly sensitive, measuring 4.25 µA/µM/cm² for CP and 4.1 µA/µM/cm² for FZ. Scan rate and concentration tests demonstrate that the oxidation of CP and FZ is a diffusion-controlled electrode process. The FPPO/MCPE sensor also demonstrates excellent repeatability, reproducibility, stability, and selectivity for detection of CP and FZ. The use of FPPO/MCPE-sensor is demonstrated for the detection of FZ and CP in milk and honey samples.

01 Nov 2024·International Journal of Antimicrobial Agents

Antibiotic resistance of Helicobacter pylori in Mainland China: A focus on geographic differences through systematic review and meta-analysis

Review

Author: Zeng, Shuyan ; Yang, Xiaoyun ; Nan, Xueping ; Li, Yueyue ; Zuo, Xiuli ; Li, Yanqing ; Wu, Xiaoqi ; Duan, Miao ; Kong, Qingzhou

BACKGROUNDEmpirical treatment needs to be supported by regional data, but knowledge of interregional differences is currently lacking in China. This study aimed to summarize and map the primary and secondary antibiotic resistance of Helicobacter pylori in different regions of mainland China.METHODSPubMed, EMBASE, Web of Science, China National Knowledge Infrastructure and Wanfang databases were systematically reviewed for studies published between 1 January 2000 and 15 July 2023. Data related to primary and secondary H. pylori antibiotic resistance rates were included. Random-effects models were used to synthesize the pooled resistance rates.RESULTSUltimately, 74 studies were included in the final analysis. A total of 16 provinces reported resistance data. The overall resistance rates of H. pylori in mainland China were 30.72% (95% CI 27.53%-33.99%) to clarithromycin, 70.14% (95% CI 29.53%-37.46%) to metronidazole and 32.98% (95% CI 28.73%-37.37%) to levofloxacin; for amoxicillin, tetracycline, and furazolidone, the rates were 2.41% (95% CI 1.43%-3.60%), 2.53% (95% CI 1.19%-4.28%) and 1.54% (95% CI 0.28%-3.62%), respectively. Spatial and temporal differences were observed. The resistance rates increased after treatment failure; however, secondary resistance to amoxicillin, tetracycline and furazolidone were still low across the vast majority of study regions.CONCLUSIONSurveillance of the updated prevalence of antibiotic resistance of H. pylori for different regions is warranted, which should factor into clinical decision making and guideline recommendations.

01 Nov 2024·Food Chemistry

Synthesis of P, N-dopped carbon nanosheets for highly sensitive fluorescence analysis of nitrofuran antibiotics in fish

Article

Author: Li, Zhuo ; Dai, Jing ; Guo, Xinrong ; Yang, Huan ; Huang, Huiqun ; Yao, Wen ; Huang, Hongyuan ; Yang, Jie

The misuse of antibiotics has caused serious impacts on food safety and human health, making it crucial to develop rapidly and highly sensitive methods for detecting trace nitrofuran antibiotics (NFs). In this study, phosphorus, nitride-doped carbon nanosheets (PN/CNs) were synthesized using a simple hydrothermal method based on graphitic carbon nitride. This prepared material showed excellent water solubility and stable optical properties. A new fluorescence sensing platform based on PN/CNs was constructed for the highly sensitive detection of four NFs. This sensitivity was mainly attributed to the fluorescence resonance energy transfer (FRET) mechanism. The limits of detection for nitrofurazone, nitrofurantoin, furazolidone and furaltadone were determined to be 13.41, 15.24, 16.37 and 19.94 nM, respectively. The high sensitivity and selectivity of PN/CNs for these four NFs were thoroughly evaluated by the Stern-Volmer equation and FRET quenching efficiency. This proposed method exhibited high sensitivity and can be successfully applied to detect NFs in fish.

100 Deals associated with Furazolidone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00830	Furazolidone	G01AX06	DB00614

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cholera	CN	Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd.	01 Jan 1981
Dysentery	CN	Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd.	01 Jan 1981
Enteritis	CN	Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd.	01 Jan 1981
Giardiasis	CN	Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd.	01 Jan 1981
Trichomonas Infections	CN	Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd.	01 Jan 1981
Typhoid Fever	CN	Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd.	01 Jan 1981

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed \| J Gastroenterol Hepatol	Not Applicable	-	-	Clarithromycin-based bismuth-containing quadruple therapy (C-BQT)	ydqoblwrbq(rklojvxnih) = Frequencies of adverse events in F-BQT and C-BQT had no differences (36.0% in C-BQT vs 32.6% in F-BQT, P = 0.499) snwksnumeo (wysqhutjvp )	Positive	01 Sep 2021
				Furazolidone-based bismuth-containing quadruple therapy (F-BQT)